1
Hopes Phillip Anthony, Parker Jeremy Stephen, Patel Bharti, Welham Matthew James: Chemical process for the preparation of an amido-phenoxybenzoic acid compound. Astrazeneca, Astrazeneca, Hopes Phillip Anthony, Parker Jeremy Stephen, Patel Bharti, Welham Matthew James, GLOBAL INTELLECTUAL PROPERTY, May 31, 2007: WO/2007/060448 (22 worldwide citation)

A process for making a compound of formula (I), (A chemical compound should be inserted here - please see paper copy enclosed herewith) (I) which is useful as an intermediate to compounds which activate glucokinase, is described, (wherein P1, R1 and R2 are as defined in the description).


2
Butters Michael, Wisedale Richard, Thomson Colin, Welham Matthew James, Watts Andrew: Process for the preparation of thiazolopyrimidines. Astrazeneca, Astrazeneca, Butters Michael, Wisedale Richard, Thomson Colin, Welham Matthew James, Watts Andrew, ASTRAZENECA, June 23, 2005: WO/2005/056563 (4 worldwide citation)

A method for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof; from a compound of the formula: (IV); wherein L represents a leaving group.


3
Gilday John Peter, Welham Matthew James: Process for the manufacture of gefitinib. Astrazeneca, Astrazeneca, Gilday John Peter, Welham Matthew James, ASTRAZENECA, March 17, 2005: WO/2005/023783 (2 worldwide citation)

The invention relates to a process for the manufacture of 4-(3'-chloro-4'- fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline which comprises the rearrangement reaction optionally in the presence of a suitable catalyst of 3-(3'-chloro-4'-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)-3,4-d ...


4
Beijer Felix, Fenner Simon, Van Eijk Peter, Welham Matthew James, Wyatt Vanessa: Cyclopropyl benzamide derivatives as intermediates for cytokine inhibitors. Astrazeneca, Astrazeneca, Beijer Felix, Fenner Simon, Van Eijk Peter, Welham Matthew James, Wyatt Vanessa, Astrazeneca Intellectual Property, November 19, 2009: WO/2009/138778

A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein Qa is as defined in the specification, the compounds being useful in the preparation of therapeutic agents, in particular cytokine inhibitors. Novel compounds of formula (I) are also provided.